EA200000433A1 - Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы - Google Patents

Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы

Info

Publication number
EA200000433A1
EA200000433A1 EA200000433A EA200000433A EA200000433A1 EA 200000433 A1 EA200000433 A1 EA 200000433A1 EA 200000433 A EA200000433 A EA 200000433A EA 200000433 A EA200000433 A EA 200000433A EA 200000433 A1 EA200000433 A1 EA 200000433A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
glycogen
phosphorilase
aldoreductase
combination
Prior art date
Application number
EA200000433A
Other languages
English (en)
Other versions
EA002365B1 (ru
Inventor
Банавара Лэкшмэн Майлари
Деннис Джей Хувер
Бернард Хьюлин
Джудит Ли Тредуэй
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200000433A1 publication Critical patent/EA200000433A1/ru
Publication of EA002365B1 publication Critical patent/EA002365B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superheterodyne Receivers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Noise Elimination (AREA)

Abstract

(57) Композиции фармацевтической комбинации и способы, включающие в себя ингибиторы альдозоредуктазы и ингибиторы гликогенфосфорилазы. Композиции и способы полезны для лечения инсулинрезистентных состояний, таких как диабет, и для снижения тканевого поражения вследствие ишемии.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000433A 1997-11-21 1998-11-02 Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы EA002365B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (2)

Publication Number Publication Date
EA200000433A1 true EA200000433A1 (ru) 2000-12-25
EA002365B1 EA002365B1 (ru) 2002-04-25

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000433A EA002365B1 (ru) 1997-11-21 1998-11-02 Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы

Country Status (38)

Country Link
EP (1) EP1032424B9 (ru)
JP (1) JP2002504478A (ru)
KR (2) KR20010032304A (ru)
CN (1) CN1279617A (ru)
AP (1) AP911A (ru)
AR (1) AR016423A1 (ru)
AT (1) ATE205403T1 (ru)
AU (1) AU733304B2 (ru)
BG (1) BG104435A (ru)
BR (1) BR9814698A (ru)
CA (1) CA2310069A1 (ru)
DE (1) DE69801680T2 (ru)
DK (1) DK1032424T3 (ru)
DZ (1) DZ2656A1 (ru)
EA (1) EA002365B1 (ru)
ES (1) ES2161548T3 (ru)
GR (1) GR3037071T3 (ru)
GT (1) GT199800166A (ru)
HR (1) HRP20000327A2 (ru)
HU (1) HUP0100272A3 (ru)
ID (1) ID24524A (ru)
IL (1) IL135713A0 (ru)
IS (1) IS5453A (ru)
MA (1) MA26568A1 (ru)
NO (1) NO20002164L (ru)
OA (1) OA11379A (ru)
PA (1) PA8462301A1 (ru)
PE (1) PE135399A1 (ru)
PL (1) PL340643A1 (ru)
PT (1) PT1032424E (ru)
SK (1) SK7222000A3 (ru)
TN (1) TNSN98211A1 (ru)
TR (1) TR200001451T2 (ru)
UA (1) UA57811C2 (ru)
UY (1) UY25258A1 (ru)
WO (1) WO1999026659A1 (ru)
YU (1) YU30700A (ru)
ZA (1) ZA9810636B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150674A1 (en) * 1999-02-12 2001-11-07 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
DE122008000018I1 (de) 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1743676A1 (en) 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CN102935081B (zh) 2005-09-14 2015-03-04 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
JP2010526146A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
EP2170864B1 (en) 2007-07-17 2011-09-14 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
ES2445917T3 (es) 2010-02-03 2014-03-06 Takeda Pharmaceutical Company Limited Inhibidores de quinasa 1 reguladora de la señal de apoptosis
BR112012025590A2 (pt) 2010-04-08 2016-06-21 Bristol Myers Squibb Co análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
EP3487862A1 (en) 2016-07-22 2019-05-29 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
WO1996039385A1 (en) * 1995-06-06 1996-12-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
EP0832065B1 (en) * 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
DE69801680D1 (de) 2001-10-18
TNSN98211A1 (fr) 2005-03-15
NO20002164L (no) 2000-07-19
CA2310069A1 (en) 1999-06-03
UA57811C2 (ru) 2003-07-15
PT1032424E (pt) 2001-12-28
AR016423A1 (es) 2001-07-04
EP1032424B9 (en) 2004-10-06
GT199800166A (es) 2000-04-19
KR20010032300A (ko) 2001-04-16
AU733304B2 (en) 2001-05-10
ATE205403T1 (de) 2001-09-15
BG104435A (bg) 2001-01-31
PL340643A1 (en) 2001-02-12
AU9555898A (en) 1999-06-15
KR20010032304A (ko) 2001-04-16
NO20002164D0 (no) 2000-04-27
MA26568A1 (fr) 2004-12-20
ZA9810636B (en) 2000-05-22
GR3037071T3 (en) 2002-01-31
DK1032424T3 (da) 2001-11-19
BR9814698A (pt) 2000-10-03
UY25258A1 (es) 2000-12-29
HUP0100272A3 (en) 2002-11-28
OA11379A (en) 2004-01-28
KR100661214B1 (ko) 2006-12-26
ID24524A (id) 2000-07-20
YU30700A (sh) 2002-12-10
EP1032424A1 (en) 2000-09-06
AP9801401A0 (en) 1998-12-31
ES2161548T3 (es) 2001-12-01
DZ2656A1 (fr) 2003-03-22
EA002365B1 (ru) 2002-04-25
HRP20000327A2 (en) 2001-02-28
IS5453A (is) 2000-04-14
TR200001451T2 (tr) 2002-06-21
WO1999026659A1 (en) 1999-06-03
IL135713A0 (en) 2001-05-20
EP1032424B1 (en) 2001-09-12
AP911A (en) 2000-12-07
CN1279617A (zh) 2001-01-10
HUP0100272A2 (hu) 2001-06-28
SK7222000A3 (en) 2001-09-11
JP2002504478A (ja) 2002-02-12
DE69801680T2 (de) 2002-02-07
PA8462301A1 (es) 2000-05-24
PE135399A1 (es) 2000-01-15

Similar Documents

Publication Publication Date Title
EA200000433A1 (ru) Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
EA200000789A1 (ru) N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
EA200600594A1 (ru) Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
EA200300793A1 (ru) Производные 3-(4-амидопиррол-2-илметилиден)-2-индолинона в качестве ингибиторов протеинкиназ
EA199900388A1 (ru) Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
EA200200316A1 (ru) Соединения для лечения ишемии
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200200806A1 (ru) Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
EA200200858A1 (ru) Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
BR9710841A (pt) Inibidores da metalproteinase matricial de bifenil-sulfonamida
EA199800773A1 (ru) Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы
EA200500849A1 (ru) Новые соединения лапахона и способы их применения
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
EA199800200A1 (ru) Ингибиторы пролилэндопептидазы
EA200000522A1 (ru) 5-htагонисты

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU